Rambabova Bushljetik Irena, Trajceska Lada, Biljali Sefedin, Balkanov Trajan, Dejanov Petar, Spasovski Goce
University Clinic for Nephrology, University Ss. Cyril and Methodius, Skopje, North Macedonia,
University Clinic for Nephrology, University Ss. Cyril and Methodius, Skopje, North Macedonia.
Blood Purif. 2021;50(4-5):492-498. doi: 10.1159/000511983. Epub 2020 Dec 8.
A new medium cut-off (MCO) membranes has been designed to achieve better removal capacities for middle and large middle molecules in hemodialysis (HD) treatment.
The aim of this study was to evaluate the removal efficacy of Theranova® in standard HD in comparison with standard high-flux HD.
Four HD patients (M/F 1/4) were included in 12-week observational pilot study in HD with Theranova® 400 and Theranova® 500 dialyzers. Each patient was assessed 4 times, T0 with high-flux dialyzers, T1 at 1 month, T2 at second month, and T3 at third month, by measuring pre- and post-HD samples of urea, Cr, β2-microglobilin (β2M), myoglobin, albumin, free light chains kappa (FLC-k), and free light chains lambda (FLC-λ).
The data showed a higher average removal rate for all the uremic toxins with Theranova® dialyzers for β2M, myoglobin, FLC-k, and FLC-λ (62.7, 56.9, 63.5, and 54.6%, respectively) during the 3 months. Albumin retention was observed and did not change between T0 and T3 (p = 0.379).
Compared to high-flux membranes, MCO membranes show greater permeability for middle molecules in midterm report.
一种新型中截留量（MCO）膜已被设计用于在血液透析（HD）治疗中对中大分子实现更好的清除能力。
本研究的目的是评估Theranova®在标准HD中与标准高通量HD相比的清除效果。
四名HD患者（男/女1/4）被纳入一项为期12周的观察性先导研究，使用Theranova® 400和Theranova® 500透析器进行HD治疗。通过测量HD前和HD后的尿素、肌酐、β2-微球蛋白（β2M）、肌红蛋白、白蛋白、游离轻链κ（FLC-k）和游离轻链λ（FLC-λ）样本，对每位患者进行4次评估，T0时使用高通量透析器，第1个月时为T1，第2个月时为T2，第3个月时为T3。
数据显示，在3个月期间，使用Theranova®透析器对所有尿毒症毒素（β2M、肌红蛋白、FLC-k和FLC-λ）的平均清除率更高（分别为62.7%、56.9%、63.5%和54.6%）。观察到白蛋白有潴留，且在T0和T3之间没有变化（p = 0.379）。
与高通量膜相比，在中期报告中，MCO膜对中分子显示出更大的通透性。
